Keywords
Schistosomiasis, Prevalence, Epidemiology, Pre-School Aged Children, Pediatric, Hard-to-reach, Praziquantel
This article is included in the Sociology of Health gateway.
This article is included in the Neglected Tropical Diseases collection.
Schistosomiasis, Prevalence, Epidemiology, Pre-School Aged Children, Pediatric, Hard-to-reach, Praziquantel
DALYs: Disability-Adjusted Life Years
NTD: Neglected Tropical Disease
PSAC: Preschool-aged Children
S. haematobium: Schistosoma haematobium
S. mansoni: Schistosoma mansoni
SAC: School-aged children
SDG: Sustainable Development Goal
Schistosomiasis is a neglected tropical disease (NTD) that affects millions of people worldwide. It is estimated that 779 million people are at risk of developing this disease.1,2 Children are the most vulnerable group to developing overt disease with 50 million preschool-age (PSAC) children in need of treatment.3 Adults are most affected by the consequences of chronic infection.4 Schistosomiasis is cause by an infection with a Schistosoma species parasite.5 There are several species, the most common being S. mansoni and S. haematobium. In a human host, the adult parasites release eggs into the environment through faeces (S. mansoni) and urine (S. haematobium). An intermediate host snail living in stagnant water is involved in the transmission cycle. Human infections take place through skin penetration when in contact with stagnant water where Schistosoma spp. larvae are present. The disease mainly affects the poorest communities without access to safe water and improved sanitation, or exposed to water during occupational and domestic activities.6,7 Symptoms of chronic schistosomiasis include anaemia, cognitive impairment, deficits in linear growth leading to chronic under-nutrition (stunting) as well as acute under-nutrition (wasting),5 genital lesions,8 and irreversible organ damage as a result of fibrosis.9 The morbidity caused by schistosomes is commonly associated with moderate-to-heavy intensities of infection as measured by the density of excreted eggs, and is progressive.10 In addition to these health consequences, schistosomiasis is associated with negative economic and social impacts.11 Estimates indicate that schistosomiasis causes an annual loss of 4.5 million disability-adjusted life years (DALYs).12
Although NTD control programs have been established in many endemic countries, the rolling out of schistosomiasis control and elimination components is still limited.13 Periodic deworming with praziquantel, the strategy recommended by WHO for the control of schistosomiasis, is available primarily to school-aged children (SAC; 5-15 years old) who can be reached efficiently through school-based programs.10 In addition to previous studies,14 the 2022 WHO guideline on control and elimination of human schistosomiasis15 has identified important treatment gaps in this strategy, including that infected PSAC are largely left untreated.
This could be because for a long time the PSAC group has been categorized as a low risk group for schistosomiasis infection16 and its impact on the health of this age group, although unknown, is often considered negligible.17 In addition, logistical and operational difficulties in collecting samples from PSAC for diagnosis, especially in hard-to-reach areas, lack of sensitive diagnostics for light schistosomiasis infections and a paucity of data on risk factors in PSAC have further biased schistosomiasis research to focus on SAC and adults over the years.16 Lastly, current donations of the main drug to treat schistosomiasis – praziquantel – are restricted to SAC.
Treatment equity is not currently achieved for schistosomiasis control as hundreds of millions of the worlds’ most vulnerable, most disadvantaged people, including PSAC, are still left behind. This is true especially for people whose incomes are below the federal poverty threshold, who live in vulnerable social and economic situation such as undocumented persons, socially excluded groups due to language, religious and other societal barriers18 and in the remotest, hardest to reach parts of endemic countries. These hard-to-reach populations are often ethnic minorities, island and fishing communities and migrant populations and other minority or marginalized populations, hindering the attainment of the Sustainable Development Goal (SDG) 3 and the commitment of global leaders to ensure that “no one is left behind” from development progress.7,19
This scoping literature review aims to document the epidemiology of pediatric schistosomiasis (children under 6 years of age) living in hard-to-reach areas and populations. In this review, hard-to-reach populations are defined following Shaghaghi et al., as: i) migrants/island and fishing communities/nomads, ii) those living in remote physical and geographical location, and iii) those living in vulnerable social and economic situation such as minority groups, undocumented persons, socially excluded groups due to language and religious barriers.18
The aim is to produce evidence on the need for inclusion of this population when designing the expansion of preventive chemotherapy to also cover those living in hard-to–reach areas. This is in accordance with the WHO guideline of 2022 on control and elimination of human schistosomiasis15 recommendation on expansion of preventive chemotherapy to cover all in need.
The condition, context, and population (CoCoPop) framework to inform the review objective is shown in Table 1.
This review will adopt the five-stage scoping review process guideline recommended by Arksey et. al.,20 taking into consideration the modifications recommended by Peters et al.21
Evidence searches
Electronic literature databases including Medline, Web of Science, Embase (Ovid), LILACS and African Journals OnLine (AJOL) will be searched for published scientific studies on pediatric schistosomiasis in hard-to reach areas, using a pre-determined search strategy (Table 2). With the guidance of a librarian (University Medical Library- University of Basel), we first developed and optimized a search strategy for PubMed. This search was then translated using the SR-accelerator tool22 developed by BOND university to generate the equivalent search terms for Embase (Ovid) and Web of Science.
Published grey literature, WHO literature databases and reports, and documentation obtained from schistosomiasis experts working in relevant organizations such as Kenya Medical Research Institute (KEMRI), Schistosomiasis Control Initiative Foundation (SCIF), Schistosomiasis Consortium for Operational Research and Evaluation (SCORE), the Foundation for Innovative New Diagnostics (FIND), Sight Savers, Hellen Keller and Merck KGaA will also be included in this review. Experts will be actively contacted with an invitation to share relevant documents and references.
All identified references will be screened independently by two reviewers (Phyllis Munyiva Isaiah and Marta Palmeirim) using a two-stage approach.
First, a manual search will be conducted on the initial hit list by reviewing the title and abstracts to identify schistosomiasis studies conducted among PSAC. Second, we will review the full texts of the shortlisted articles to identify studies conducted in hard-to-reach areas and populations.
Additional references will then be retrieved by manually searching the bibliographies of identified articles. All relevant literatures will be downloaded into EndNote X9 to maintain and manage citation and facilitate the overall review process.
Inclusion/exclusion criteria
We will include cross-sectional, cohort and case control studies on schistosomiasis in children under 6 years old and living in hard-to-reach areas or belonging to hard-to-reach populations. Similar studies done on women of reproductive age and adults; or studies that did not apply cross-sectional or cohort or case control design (e.g. case reports) will be excluded from the review.
Reviewers will assess all included studies independently for possible bias by using the Joanna Briggs Institute (JBI) Prevalence Critical Appraisal Tool.23 All selected studies will be assessed using the 10 quality control items suggested by the tool. A score of 1 will be awarded for each item fulfilled while a 0 score will be awarded for each unfilled control item. Score aggregates will then be generated and converted into a low, moderate and high quality classification.24 Poor quality studies will be excluded, clearly documenting the reason for exclusion.
Data will be extracted from included documents and exported to a predefined summary template in Microsoft excel 2016. Extracted data will include:
i. Bibliographic information (first author, journal/document, year of publication)
ii. Year and country of study
iii. Sample size
iv. Study population age and sex
v. Prevalence and/or incidence of schistosomiasis
vi. Mean eggs per gram of feces or infection intensity classification (if available)
vii. Specific schistosome species observed
viii. Diagnostic method
ix. Type of hard-to-reach population/area
Extracted data will be analyzed using IBM SPSS statistics V.24. Descriptive statistics will be performed to allow for narrative synthesis. Weighted population mean outcomes will then be calculated for prevalence among PSAC.25 To calculate pooled prevalence estimates (PPE), the inverse variance heterogeneity (IVhet) model26 in MetaXL will be used for the selected studies, to ensure that statistical error is not underestimated.24 The level of heterogeneity on selected studies will be evaluated using Cochran’s Q and I2 statistics. This will be done by stratifying our data according to schistosomiasis prevalence and the region where the studies were conducted to determine heterogeneity between subgroups and within-groups.24 Forest plots will be used to show the estimated prevalence (95% confidence interval).
We acknowledge Dr. Thomas Fürst (University Medical Library- University of Basel) for his input and guidance in developing and optimizing search strategies used in this review.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Partly
Are sufficient details of the methods provided to allow replication by others?
Partly
Are the datasets clearly presented in a useable and accessible format?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Epidemiolgoy of schistosomiasis
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Tropical Diseases
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 2 (revision) 20 Jan 23 |
read | read |
Version 1 21 Oct 22 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)